Floatz logo

TRASTUZUMAB

Circulating Tumor Cells

European Organisation for Research and Treatment of Cancer - EORTCmonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Circulating Tumor Cells cohort.

Asset / SponsorPhaseRating
Desflurane
Zhejiang Cancer Hospital
Phase 4BBB
PROPOFOL
Zhejiang Cancer Hospital
Phase 2B
Rocuronium
Zhejiang Cancer Hospital
Phase 2B
Docetaxel
UNICANCER
Phase 2B
CABAZITAXEL
UNICANCER
Phase 2B
Acetylsalicylic Acid
Zhejiang Provincial People's Hospital
Phase 2CCC

Same molecule, other indications

TRASTUZUMAB is also rated in:

breast carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
inflammatory breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
HER2/Neu PositiveDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →